Latest United States News

Foresta Group Holdings has received allowance from the USPTO for its US patent application covering its proprietary rosin and terpene production process, expected to protect its technology until at least 2041.

PainChek announces the immediate departure of CEO Philip Daffas, with COO Andy Hoggan stepping in as interim leader amid a strategic pivot to boost US market growth following FDA clearance.

Stakk Limited is set to become a global powerhouse in AI-driven Digital Trust infrastructure following its US$63 million acquisition of ParaScript, a leader in AI-powered document intelligence and fraud detection. The deal significantly boosts Stakk's scale, technology, and recurring revenue base, underpinning a robust growth trajectory.

ReNerve Limited has secured regulatory approval to market its flagship NervAlign Nerve Cuff in Indonesia, marking a major step in its Asia-Pacific expansion and unlocking access to one of the region’s largest nerve repair markets.

Union Star Metals has locked in a binding option agreement with Lionex Metals Group for its Kalgoorlie Gold Project, potentially netting up to A$890,000. The deal aligns with Union Star’s strategy to streamline Australian assets and refocus on its Nevada gold and silver ventures.

Diablo Resources has secured final permits to start a maiden diamond drilling program at its high-grade North Star Prospect in Utah, targeting silver, antimony, and copper. The company also completed the second tranche of a $3.5 million placement to fund exploration and the Horn Silver acquisition.

First Graphene has signed an MOU with Sixth Element to distribute its PureGRAPH® CEM additive across China, with potential for local manufacturing via a joint venture once sales milestones are met.

KGL Resources has launched a $120 million entitlement offer at $0.20 per share, part of a $300 million capital raise to fund the Jervois Copper Project. The offer is underwritten except for pre-commitments from major shareholders, with new shares expected to be issued late July.

Atlas Arteria has lodged its seventh supplementary target’s statement, reinforcing the Independent Directors’ unanimous recommendation to reject IFM Global Infrastructure Fund’s takeover offer. The statement highlights the strategic rationale behind settling a US$100 million put option with Ontario Teachers’ Pension Plan and outlines risks tied to IFM’s majority ownership.

OncoSil Medical has submitted its Humanitarian Device Exemption application to the FDA for its OncoSil™ device targeting distal cholangiocarcinoma, entering the final review phase with a decision expected within 45 days.

Cyclopharm Limited delivered a record $17.1 million in revenue for 1H FY26, driven by a 73% surge in US Technegas® sales. However, delays in clinical guideline publication have pushed the short-term US installation target beyond 2026, while medium-term ambitions remain intact.

Neurotech International has received Notices of Allowance from the USPTO for two patents covering its lead drug NTI164, reinforcing its intellectual property position as it advances Phase 3 trials for autism spectrum disorder.